Mast Cell Activation Disorders

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 3, 2014, Pages 252-257.e1

  Akin, Cem ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diagnosis; Mast cell activation syndromes; Mast cells; Mastocytosis; Treatment; Tryptase c kit

Indexed keywords

ADRENALIN; ALPHA INTERFERON; CLADRIBINE; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DAPSONE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; KETOTIFEN; OMALIZUMAB; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; IMMUNOLOGIC FACTOR;

ALLERGIC REACTION; BONE MARROW BIOPSY; CELL ACTIVATION; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG EFFICACY; HUMAN; IDIOPATHIC SYSTEMIC MAST CELL ACTIVATION SYNDROME; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MAST CELL; MAST CELL ACTIVATION DISORDER; MAST CELL DEGRANULATION; MASTOCYTOSIS; MICROENVIRONMENT; MONOCLONAL MAST CELL ACTIVATION SYNDROME; REVIEW; SERODIAGNOSIS; TREATMENT RESPONSE; IMMUNOLOGY;

ANTI-ALLERGIC AGENTS; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOLOGIC FACTORS; MASTOCYTOSIS;

EID: 84899714851     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.03.007     Document Type: Review

References (52)

1. Galli S.J., Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010, 40:1843-1851.
2. Gilfillan A.M., Austin S.J., Metcalfe D.D. Mast cell biology: introduction and overview. Adv Exp Med Biol 2011, 716:2-12.
3. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26:465-485.
4. Sampson H.A., Munoz-Furlong A., Campbell R.L., Adkinson N.F., Bock S.A., Branum A., et al. Second symposium on the definition and management of anaphylaxis: summary report: Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391-397.
5. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126:1099-1104.e4.
6. Yell J.A., Mbuagbaw J., Burge S.M. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996, 135:355-362.
7. Diogenes M.J., Diogenes P.C., de Morais Carneiro R.M., Neto C.C., Duarte F.B., Holanda R.R. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol 2004, 43:632-637.
8. Confino-Cohen R., Chodick G., Shalev V., Leshno M., Kimhi O., Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012, 129:1307-1313.
9. Wedi B., Raap U., Wieczorek D., Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol 2009, 5:10.
10. Jawed S.I., Myskowski P.L., Horwitz S., Moskowitz A., Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014, 70:205.e1-205.e16. quiz 21-2.
11. Rubenstein M., Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol 2006, 45:251-256.
12. Abonia J.P., Blanchard C., Butz B.B., Rainey H.F., Collins M.H., Stringer K., et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010, 126:140-149.
13. Valent P., Akin C., Arock M., Brockow K., Butterfield J.H., Carter M.C., et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012, 157:215-225.
14. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
15. Horny H.P., Metcalfe D.D., Bennett J.M., Bain B.J., Akin C., Escribano L., et al. Mastocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 54-63. IARC Press, Lyon, France. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
16. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
17. Bodemer C., Hermine O., Palmerini F., Yang Y., Grandpeix-Guyodo C., Leventhal P.S., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
18. Kristensen T., Vestergaard H., Bindslev-Jensen C., Moller M.B., Broesby-Olsen S. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014, doi: 10.1002/ajh.23672. [Epub ahead of print].
19. Akin C. Multilineage hematopoietic involvement in systemic mastocytosis. Leuk Res 2003, 27:877-878.
20. Teodosio C., Garcia-Montero A.C., Jara-Acevedo M., Alvarez-Twose I., Sanchez-Munoz L., Almeida J., et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012, 26:951-958.
21. Hartmann K., Henz B.M. Cutaneous mastocytosis: clinical heterogeneity. Int Arch Allergy Immunol 2002, 127:143-146.
22. Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25:519-528.
23. Akin C., Scott L.M., Kocabas C.N., Kushnir-Sukhov N., Brittain E., Noel P., et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331-2333.
24. Alvarez-Twose I., Gonzalez de Olano D., Sanchez-Munoz L., Matito A., Esteban-Lopez M.I., Vega A., et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010, 125:1269-1278.e2.
25. Schwartz L.B., Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:641-657.
26. Alvarez-Twose I., Gonzalez-de-Olano D., Sanchez-Munoz L., Matito A., Jara-Acevedo M., Teodosio C., et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2012, 157:275-280.
27. Valent P., Aberer E., Beham-Schmid C., Fellinger C., Fuchs W., Gleixner K.V., et al. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am J Blood Res 2013, 3:174-180.
28. Sperr W.R., El-Samahi A., Kundi M., Girschikofsky M., Winkler S., Lutz D., et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009, 39:914-923.
29. Siles R., Xu M., Hsieh F.H. The utility of serum tryptase as a marker in chronic spontaneous urticaria. Acta Derm Venereol 2013, 93:354-355.
30. Ferrer M., Nunez-Cordoba J.M., Luquin E., Grattan C.E., De la Borbolla J.M., Sanz M.L., et al. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy 2010, 40:1760-1766.
31. Dugas-Breit S., Schopf P., Dugas M., Schiffl H., Rueff F., Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005, 3:343-347.
32. Schwartz L.B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006, 26:451-463.
33. Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12:259-270.
34. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Dal Fior D., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009, 123:680-686.
35. Oude Elberink J.N., de Monchy J.G., Kors J.W., van Doormaal J.J., Dubois A.E. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997, 99:153-154.
36. Rueff F., Przybilla B., Bilo M.B., Muller U., Scheipl F., Aberer W., et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010, 126:105-111.e5.
37. Rueff F., Vos B., Elberink J.O., Bender A., Chatelain R., Dugas-Breit S., et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014, doi: 10.1111/cea.12275. [Epub ahead of print].
38. Bridgman D.E., Clarke R., Sadleir P.H., Stedmon J.J., Platt P. Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases. Anaesth Intensive Care 2013, 41:116-121.
39. van Doormaal J.J., van der Veer E., van Voorst Vader P.C., Kluin P.M., Mulder A.B., van der Heide S., et al. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy 2012, 67:683-690.
40. Lee M.J., Akin C. Mast cell activation syndromes. Ann Allergy Asthma Immunol 2013, 111:5-8.
41. Schwartz L.B., Metcalfe D.D., Miller J.S., Earl H., Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987, 316:1622-1626.
42. Butterfield J.H., Weiler C.R. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol 2008, 147:338-343.
43. Hamilton M.J., Hornick J.L., Akin C., Castells M.C., Greenberger N.J. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011, 128:147-152.e2.
44. Molderings G.J., Haenisch B., Bogdanow M., Fimmers R., Nothen M.M. Familial occurrence of systemic mast cell activation disease. PLoS One 2013, 8:e76241.
45. Cardet J.C., Akin C., Lee M.J. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013, 14:2033-2045.
46. Ditto A.M., Harris K.E., Krasnick J., Miller M.A., Patterson R. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996, 77:285-291.
47. Carter M.C., Robyn J.A., Bressler P.B., Walker J.C., Shapiro G.G., Metcalfe D.D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007, 119:1550-1551.
48. Bell M.C., Jackson D.J. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012, 108:383-384.
49. Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64:1384-1385.
50. Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010, 116:5812-5817.
51. Krauth M.T., Mirkina I., Herrmann H., Baumgartner C., Kneidinger M., Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009, 39:1711-1720.
52. Kneidinger M., Schmidt U., Rix U., Gleixner K.V., Vales A., Baumgartner C., et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008, 111:3097-3107.